Patents by Inventor Yucheng Li

Yucheng Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
    Patent number: 8148106
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
  • ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES
    Publication number: 20110223155
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Application
    Filed: February 8, 2011
    Publication date: September 15, 2011
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
  • Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
    Patent number: 7935791
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: May 3, 2011
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
  • Thymic stromal lymphpoietin promoter and use therefor
    Publication number: 20090156467
    Abstract: A promoter comprising the isolated promoter region of the human Thymic Stromal Lymphopoietin (TSLP) gene and functional portions of the promoter region having TSLP promoter activity. The promoters are useful for identifying promoter agonists and antagonists that can be used to prevent or treat allergic conditions and autoimmune diseases.
    Type: Application
    Filed: July 27, 2005
    Publication date: June 18, 2009
    Inventors: Zhengbin Yao, Guanghui Hu, Yucheng Li, Kang Li
  • ANTAGONIST ANTI-NOTCH3 ANTIBODIES AND THEIR USE IN THE PREVENTION AND TREATMENT OF NOTCH3-RELATED DISEASES
    Publication number: 20080226621
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Application
    Filed: December 17, 2007
    Publication date: September 18, 2008
    Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
  • Human mast cell-expressed membrane proteins
    Publication number: 20050288487
    Abstract: Mast cell-expressed membrane proteins that are highly expressed in human mast cells and the lungs as compared to brain, heart, kidney, liver, tracheal, and similar tissues. The proteins are transmembrane proteins involved in the regulation of mast cell and lung tissue function, including degranulation of mast cells. The preferred protein is a 187 amino acid transmembrane protein having an intercellular domain comprising amino acids 1 through 82, a transmembrane domain comprising amino acids 83 through 105, and an extracellular domain comprising amino acids 106 through 187 (SEQ ID NO:2).
    Type: Application
    Filed: January 3, 2003
    Publication date: December 29, 2005
    Inventors: Kang Li, Yucheng Li, Shen-Wu Wang, Guanghui Hu, Zhengbin Yao
  • B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
    Publication number: 20030147887
    Abstract: The present invention provides vaccines, antibodies, and diagnostic tools for the diagnosis and/or treatment of B-cell mediated diseases, particularly B-cell lymphomas.
    Type: Application
    Filed: November 2, 2002
    Publication date: August 7, 2003
    Inventors: Shen-Wu Wang, Guanghui Hu, Yucheng Li, Zhengbin Yao